Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress ("ESMO")
Stock Information for Zymeworks Inc.
Loading
Please wait while we load your information from QuoteMedia.